Founded in 2010, the company is headquartered in Singapore and has offices in Taiwan and China.

ASLAN is developing eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis (AD) with the potential to improve upon current biologics used to treat allergic disease, and reported positive topline data in Q2 2023 from a Phase IIb dose ranging study in moderate-to-severe AD.

ASLAN is also developing farudodstat, a potent oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) as a potential first-in-class treatment for alopecia areata (AA) in a Phase 2a proof-of-concept trial with an interim readout expected in Q1 2024.